Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus E E
Eur J Clin Pharmacol. 1986;31(1):59-62. doi: 10.1007/BF00870987.
In 6 healthy volunteers the pharmacokinetics of bisoprolol under steady-state conditions was investigated over three consecutive phases: over 7 days of 10 mg of bisoprolol once daily per os, 7 days of 10 mg of bisoprolol once daily plus 400 mg of cimetidine t.i.d. and 14 days of 10 mg of bisoprolol and 600 mg of rifampicin once daily with adequate intervals free of medication. After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h. Cimetidine did not cause any significant changes in the pharmacokinetics of bisoprolol. Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h). Accordingly, total body clearance increased to 23.8 +/- 2.5 l/h (p less than 0.05). In conclusion bisoprolol showed a statistically significant but probably clinically not important interaction with the enzyme-inducing drug rifampicin, but not with the enzyme inhibitor cimetidine.
在6名健康志愿者中,在稳态条件下对比索洛尔的药代动力学进行了连续三个阶段的研究:每天口服10 mg比索洛尔,持续7天;每天口服10 mg比索洛尔加400 mg西咪替丁,每日3次,持续7天;每天口服10 mg比索洛尔和600 mg利福平,持续14天,且在各阶段之间有足够的无药物间隔期。单独使用比索洛尔治疗后,β受体阻滞剂的血浆峰值水平(Cssmax)为55.5±6.4 ng/ml(平均值±标准误),血浆水平-时间曲线下面积(AUC tau)为597±70 ng/ml·h,总体清除率(CL)为15.8±1.8 l/h,消除半衰期(t1/2β)为10.1±1.2 h。西咪替丁对比索洛尔的药代动力学没有引起任何显著变化。利福平的联合给药导致Cssmax(43.0±6.9 ng/ml)、AUC tau(397±54 ng/ml·h)和t1/2β(6.2±0.4 h)降低。相应地,总体清除率增加到23.8±2.5 l/h(p<0.05)。总之,比索洛尔与酶诱导药物利福平存在统计学上显著但可能临床上并不重要的相互作用,但与酶抑制剂西咪替丁不存在相互作用。